我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

吡格列酮对自发性高血压大鼠心脏成纤维细胞周期的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第3期
页码:
305-308
栏目:
基础研究
出版日期:
2008-05-20

文章信息/Info

Title:
Effects of Pioglitazone on cell cycle of cardiac fibroblasts in spontaneous hypertesion rats
作者:
于心亚1; 刘朝中1; 赵连友2; 田建伟2; 张海涛1
1.北京空军总医院心血管内科，北京 100036； 2.第四军医大学唐都医院心血管内科，陕西 西安 710038
Author(s):
YU Xinya1;  LIU Chaozhong1;  ZHAO Lianyou2;  TIAN Jianwei1;  ZHANG Haitao1
1.Department of Cardiology, General Hospital of Air Force, Beijing 100036, China; 2.Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China
关键词:
细胞周期; 吡格列酮; 自发性高血压大鼠; 心脏成纤维细胞
Keywords:
cell cycle; pioglitazone; spontaneous hypertesion rat; cardiac fibroblasts
分类号:
R329.24
DOI:
-
文献标识码:
A
摘要:
目的 研究盐酸吡格列酮对培养的自发性高血压大鼠（SHR）和血压正常大鼠（WKY）心脏成纤维细胞（CFs）细胞周期的影响，并进一步探讨其与NONOS系统的关系。方法 采用胶原酶消化法培养SHR和WKY的CFs，流式细胞仪（FCM）分析技术检测细胞周期，硝酸还原酶法测定CFs培养上清NO浓度，分光光度法测定CFs培养上清NOS活性。结果 0.1、1、5和10 μmol/L的吡格列酮作用48 h后，SHR、WKY CFs的G0/G1期细胞百分率较对照组显著增高（均P<0.01），S期细胞百分率、G2/M期细胞百分率和增殖指数则显著低于对照组（P<001，P<005），且随着作用浓度的增加，吡格列酮对细胞周期的影响逐渐增强。5 μmol/L的吡格列酮干预48 h后，SHR和WKY的CFs培养上清NO浓度分别为（111.2±12.4）μmol/L和（221.7±35.3）μmol/L，与各自对照组（76.8±2.4） μmol/L、（112.1±8.9） μmol/L相比，差异非常显著（P<0.01）；SHR和WKY大鼠CFs培养上清NOS活性分别为(208±18)μkat/L、(257±30)μkat/L，和各自对照组（148±10）μkat/L、(187±8)μkat/L相比，亦有非常显著性差异（P<001）。NO浓度和NOS活性呈显著正相关(r=0.964，P<0.01)。结论 吡格列酮能够抑制SHR CFs的细胞周期增殖，其效应可能与上调NONOS系统活性有关。
Abstract:
AIM To evaluate the effects of insulinsensitizer Pioglitazone on the cell cycle of cardiac fibroblasts (CFs) isolated from SHR and WKY rat and the activity of NONOS. METHODS Isolated and cultured CFs of SHR and WKY rats were used as experiment model. Cell cycle was determined by FCM. Nitrate enzyme reverting methods and spectrophotometer were also adopted to detect the content of NO and activity of NOS in CFs of SHR and WKY rats with or without Pioglitazone. RESULTS Based on the analysis of FCM cell cycle, it was shown that the percentage of cells on S and PI stages in CFs of SHR and Wistar was gradually declined as Pioglitazone concentration increased, while the percentage of cells on G0/G1 stages rose（P<0.01）. In SHR and Wistar rats, the NO concentration in supernatant (111.2±12.4) μmol/L, (221.7±35.3) μmol/L, respectively treated by 5 μmol/L pioglitazone for 48 hours, was significantly higher than that of control group (76.8±2.4) μmol/L, (112.1±8.9)μmol/L, respectively, P<001. NOS activity in supernatant of SHR and Wistar rats［(208±18)μkat/L,（257±30） μkat/L, respectively］ treated by 5 μmol/L pioglitazone for 48 hours, was also significantly higher than that of control group (148±10) μkat/L, (187±8) μkat/L, respectively, P<001. There was a significantly positive correlation between NO contents and NOS activity (r=0964, P<001). CONCLUSION Insulinsensitizer hydrochloride Pioglitazone inhabits the cell cycle proliferation of CFs of SHR in vitro, which may related with the upregulation of NONOS system.

参考文献/References

［1］ 李榕， 姬秋和,马恒，等.胰岛素对自发性高血压大鼠离体主动脉的舒张作用及机制［J］. 心脏杂志， 2003， 15（6）：501-503,507.

［2］ 郝广华，牛小麟.过氧化物酶体激活物受体γ与左室重构［J］. 心脏杂志， 2006， 18（2）：237-238.

［3］ 周裔忠，王洪，祝善俊，等.以左室质量百分比探讨高血压病左室重构与胰岛素抵抗、血脂异常的关系［J］. 心脏杂志， 2005， 17（6）：586-588,591.

［4］ 李永勤，牛小麟，李少民，等.高血压病患者动脉血管组织中PPARγ的表达［J］. 心脏杂志， 2005， 17（5）：416-418.

［5］ 李月英，宋瑜璋. 高血压病患者胰岛素抵抗及其关联因素［J］. 心脏杂志， 2004， 16（4）：349-350,353.

［6］ Nash DT. Insulin Resistance, ADMA level, and Cardiovascular Disease［J］. JAMA, 2002, 287(11):1451-1452.

［7］ Stuhlinger MC,Abbasi F,Chu JW. et al. Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthese Inhibitor［J］. JAMA, 2002， 287(11)：1420-1426.

［8］ Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms［J］. Ann Med, 2002, 34(3):217-224.

［9］ Aizawa Y, Kawabe J, Hasebe N, et al. Pioglitazone enhances cytokineinduced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia［J］. Circulation, 2001, 104(4):455-60.

［10］Igarashi M, Hirata A, Yamaguchi H, et al. Characterization of an inhibitory effect of pioglitazone on ballooninjured vascular smooth muscle cell growth［J］. Metabolism, 2001, 50(8):955-962.

［11］Sakai S, Miyauchi T, IrukayamaTomobe Y, et al. Peroxisome proliferatoractivated receptorgamma activators inhibit endothelin1related cardiac hypertrophy in rats［J］. Clin Sci, 2002, 103 (Suppl 1):16S-20S.

［12］Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension［J］. N Engl J Med, 1987, 317(6):350-357.

［13］Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records［J］. Clin Ther, 2002, 24(3):378-396.

［14］Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus［J］. Circulation, 2002, 106(6):679-684.

［15］Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantationassociated arteriosclerosis［J］. Circ Res, 2002, 90:703-710.

［16］Kawakami S, Arai G, Hayashi T, et al. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro［J］. J Cell Physiol, 2002, 191(3):310-319.

［17］Rumi MA, Sato H, Ishihara S, et al. Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferatoractivated receptorgamma ligands［J］. J Lab Clin Med, 2002, 140(1):17-26.

备注/Memo

备注/Memo:
收稿日期：2007-01-27.作者简介：于心亚，主治医师，硕士Email:xinyay@sohu.com
更新日期/Last Update: